Saudi Arabia The Saudi medtech market was valued at USD 2.25 billion in 2017 and is expected to reach USD 3.87 billion at a CAGR of 9.5 percent by 2023, according to Market Research Future. Like other parts of the Saudi healthcare continuum, the country’s medtech industry is extremely dynamic and changing…

Saudi Arabia Historic Saudi healthcare firm Tamer Group has transitioned from a distributor into one of the country’s leading fully-fledged pharmaceutical companies since the 1990s, aided in large part by strategic partnerships with leading Japanese firms. With the family-owned firm seeking further progression, Chairman and Managing Partner Aymen Tamer highlights his vision…

Saudi Arabia Saudi Arabia’s response to COVID-19 stands up well to international comparisons in both the MENA region and globally. In recent conversation with PharmaBoardroom, Fahad Al Shebel, CEO of national medicine procurement body NUPCO, outlines some of the fundamentals behind this success story.   Extreme, But Effective, Measures Saudi Arabia took…

Saudi Arabia Few stakeholders are better placed to assess the landscape for rare disease therapies across the Middle East and North Africa (MENA) region than Karim Smaira and Kamel Ghammachi of Genpharm, an entrepreneurial success story that now provides market access and marketing solutions for rare disease products across the region.  …

Africa Medicines for Africa’s Lenias Hwenda highlights the vast gaps in COVID-19 vaccine access globally, especially in Africa where just six percent of the population has been vaccinated. Hwenda argues that the time is now to boost the infrastructure for pharmaceutical manufacturing in Africa as a way out of this pandemic,…

Turkey With an already well-established manufacturing industry for pharmaceuticals, Turkey has been aiming to move with global trends and invest in biologics production, specifically in biosimilars.   The share of biotechnological pharmaceuticals has reached 30 percent globally, a rate that is expected to continue increasing, but the market share in Turkey…

Turkey Becoming the clinical trials country leader in the region has been set as a primary goal for Turkey’s pharma industry to achieve global competitiveness. The government’s strategy is to increase its share of global clinical studies both in numbers and investment. Today, the country occupies the 26th position with 529…

Turkey Few Turkish companies are experiencing such a transformational moment as GEN. In 2021 alone, the Ankara-based organization made its public debut on the Istanbul Stock Exchange and signed an exclusive collaboration agreement with Dutch biotech Sulfateq BV for the development and commercialization of a therapy against Alzheimer’s and other neurodegenerative…

Turkey When the Turkish Ministry of Health implemented its strategy to transition from import pharmaceuticals to manufacturing them at home in 2016, the local industry leveraged the situation to invest in new technology and increase their manufacturing capacity. A few multinational innovators took the opportunity to invest in their own plants,…

Turkey As an upper-middle-income country with an emerging economy, Turkey could not invest billions in COVID-19 vaccine R&D, but a strong research ecosystem and willing industry allowed it to kickstart multiple vaccine and drug projects, discovering a new collaborative model along the way.   The responsibility for coordinating Turkey’s research and…

Turkey Overseeing healthcare for a population of over 80 million, Turkey’s Ministry of Health was put under the spotlight during the COVID-19 pandemic. Here, we highlight four of the hot-button items on Minister of Health Dr Fahrettin Koca’s plate as Turkey emerges from the pandemic period.   Pandemic Learnings A few…

Turkey There are perhaps no two words that better summarize the last few years in Turkish pharma than localization and pricing. But after years of investment and struggles, the country’s priorities appear to be shifting. Turkey’s Vision 2023, as defined in its 11th Development Plan, has changed the government’s vision regarding…